GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024

CRESCENT BIOPHARMA, INC.

Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.
Phase 3 uproleselan topline results expected Q2 2024; NDA submission by end-2024 if positive.
Phase 1a GMI-1687 met primary and secondary endpoints; research agreement with ASH RC for SCD.
R&D expenses FY2023 $20.1M (down from $28.4M); G&A $19.2M (flat vs $19.1M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRESCENT BIOPHARMA, INC. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-004015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.